The USPTO Patent Trial and Appeals Board (PTAB) declined to institute Inter Partes Review (IPR) proceedings against three Biogen Idec TYSABRI patents. The IPR petitions were filed by Swiss Pharma International, and asserted¬†obviousness based on references that disclosed antibody formulations similar to those claimed in the Biogen patents, but did not teach the high antibody … Continue reading this entry